货号:A567818 同义名: PF-06650833 产品仅供科研
PF-06650833 is an inhibitor ofInterleukin-1 receptor associated kinase 4 (IRAK4), and used to treat diseases such as rheumatoid arthritis, lupus, and lymphomas.
规格 | 价格 | 会员价 | 库存 | 数量 | |||
---|---|---|---|---|---|---|---|
{[ item.pr_size ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} | 现货 | 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费分装
免费溶解
描述 | Zimlovisertib (PF-06650833) is a potent, selective, and orally bioavailable inhibitor of interleukin-1 receptor-associated kinase 4 (IRAK4), showing IC50 values of 0.2 nM in cell assays and 2.4 nM in peripheral blood mononuclear cell (PBMC) assays. It is primarily aimed at treating conditions such as rheumatoid arthritis, lupus, and lymphomas[1].[2]. In a kinome profiling study involving 278 kinases at a concentration of 200 nM, Zimlovisertib exhibited near-total inhibition of IRAK4 activity[1]. Zimlovisertib's specificity was further evaluated in a whole cell functional VEGF2R assay using the PAE-KDR cell line, where it showed no activity at concentrations up to 30 μM. Additionally, at 100 μM, Zimlovisertib was found to inhibit the hERG current by 25% in a voltage clamp assay[1]. Investigations into Zimlovisertib's effect on major CYP450 enzymes, using pooled human liver microsomes and specific probe substrates, indicated less than 5% inhibition of CYPs 1A2, 2C8, 2C9, 2D6, and 3A4 at 3 μM. Moreover, no time-dependent inhibition of these enzymes was observed even at 100 μM. Zimlovisertib, at 10 μM, led to a 4.4-fold increase in CYP3A mRNA in cryopreserved human hepatocytes, suggesting potential induction effects[1]. |
Animal study | Oral administration of Zimlovisertib (0.3-30 mg/kg) to male Sprague-Dawley rats significantly suppressed LPS-induced TNF-α production in a dose-dependent manner. Plasma concentrations of Zimlovisertib were measured at 2.1 nM, 7.7 nM, 19 nM, and 150 nM free, respectively, 2.5 hours post-administration at the aforementioned dosages. The fraction of Zimlovisertib unbound in rat plasma was determined to be 0.3[1]. |
计算器 | ||||
存储液制备 | 1mg | 5mg | 10mg | |
1 mM 5 mM 10 mM |
2.77mL 0.55mL 0.28mL |
13.84mL 2.77mL 1.38mL |
27.67mL 5.53mL 2.77mL |
CAS号 | 1817626-54-2 |
分子式 | C18H20FN3O4 |
分子量 | 361.368 |
别名 | PF-06650833 |
运输 | 蓝冰 |
存储条件 |
粉末 Sealed in dry,2-8°C 液体 -20°C:3-6个月-80°C:12个月 |
溶解度 |
DMSO: 60 mg/mL(166.04 mM),配合低频超声,并水浴加热至45℃助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO |
动物实验配方 |